Carregant...
Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the USA with a 5-year survival rate less than 3% to 5%. Gemcitabine remains as a standard care for PDAC patients. Although protein neddylation is abnormally activated in many human cancers, whether neddylation dys...
Guardat en:
| Publicat a: | Neoplasia |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Neoplasia Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5440286/ https://ncbi.nlm.nih.gov/pubmed/28535453 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2017.04.003 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|